Pharmaceutical

AstraZeneca’s Tagrisso gains approval in Canada for NSCLC

AstraZeneca has obtained Health Canada’s Notice of Compliance (NOC) for Tagrisso (osimertinib) to treat NSCLC.

Jul 16, 2024 - 04:00
AstraZeneca’s Tagrisso gains approval in Canada for NSCLC
AstraZeneca has obtained Health Canada’s Notice of Compliance (NOC) for Tagrisso (osimertinib) to treat NSCLC.
Read the original article

Tags:

Previous Article

Mabwell’s 9MW2821 gains FDA fast track status for breast cancer

Next Article

New study reveals more struggling to afford healthcare

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

BGB-26808 by BeiGene for Solid Tumor: Likelihood of App...

Oct 3, 2023

Inflationary pressure causes drop-off in contract manufacturing M&A

Inflationary pressure causes drop-off in contract manuf...

Jul 29, 2023

STAT+: Here’s who’s profiting the most in health care

STAT+: Here’s who’s profiting the most in health care

Jan 2, 2024